Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 13, 2006

View Archived Issues

Roche and Amira sign research collaboration and licensing option agreements

Cellegesic to be reviewed by FDA Advisory Committee in April

Preclinical findings show Miraxion has neuroprotective effects in Parkinson's

Second phase I trial begins for third-generation taxane TPI-287

Series B financing to support pipeline development at Xytis

Hana demonstrates bioequivalence of Zensana ondansetron oral spray

TAP terminates sublicensing agreement with Santarus

IND submission for BEMA LA for moderate to severe pain

Enrollment open in phase IIb kidney transplant study of ISA-247

Phase I study for PV-903 for treatment of recurrent miscarriages

Ibuprofen may delay or prevent PD

MUC1 immunoassay may detect pancreatic cancer

Neurocrine updates FDA review of indiplon NDAs

Hemopure to be submitted for European approval in mid-2006

EntreMed completes Miikana acquisition

PR Pharmaceuticals and OSI collaborate on sustained-release Macugen

GlobeImmune closes Series B financing

European orphan drug designation for Amplimexon in ovarian cancer

MRE-0094 enters phase II for chronic neuropathic diabetic foot ulcers

Phase III program commences for Vanquix for acute, repetitive epileptic seizures

New analogue of celecoxib mimics antitumor activity in MM without COX-2 inhibition

Novel antiinfective agents disclosed in recent Johnson & Johnson patent

Vitragan MAA accepted for review

Recent patents report new therapeutic agents for diabetes and other endocrine-related disorders

Fast track designation for FavId in B-cell follicular NHL

LSN-2120310's activity against a wide range of menopausal symptoms

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...